HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress Instructs FDA On Nanotech Work, But Mute On Funding

This article was originally published in The Rose Sheet

Executive Summary

Newly passed user-fee legislation includes a provision directing FDA to intensify its research and policy development regarding nanotechnology and its use in consumer products. How such efforts are to be funded remains a question.

You may also be interested in...

FDA Global Panel Focuses On Developing Countries’ Reg Systems

An FDA Science Board subcommittee will assess safety awareness in countries exporting food and medical products to the U.S. and identify potential strategies for strengthening regulatory systems in those countries, says Chairman Jeff Bender.

Safety Testing For Nano-Cosmetics Must Address Actual Use Scenarios

Study on powder-based cosmetics self-identified as incorporating nanotechnology finds that nanomaterials released through product use and inhaled do not deposit in the respiratory system where one might expect them to. Investigators conclude that marketers must take into consideration not only the safety of pure nano-ingredients but also their fate with actual product use.

House, Senate Differ In Treating FDA China Syndrome

Appropriators in the House and Senate endorse FDA’s plan to spend $10 million more on inspections in China in 2013, but only the Senate approves increasing the agency’s budget to cover the costs. FDA’s request for China inspections includes $5.6 million for inspections at drug facilities.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts